In this cohort analysis, intensive systolic blood pressure control was associated with a lower risk of major adverse cardiovascular events across stages of cardiovascular-kidney-metabolic syndrome compared with standard targets. Benefit-to-harm profiles remained favorable across risk strata, supporting lower blood pressure targets in appropriately selected patients with elevated cardiometabolic risk.

Source: JAMA Network Open